Last reviewed · How we verify
NCT05527782
A Phase II Study of Efficacy and Safety of Induction Modified TPF (mTPF) Followed by Concurrent Chemoradiotherapy (CCRT) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)
Phase 2 trial testing modified TPF in Locally Advanced Head and Neck Squamous Cell Carcinoma in 40 participants. Participants enrolled and being followed up; not accepting new ones.
1 August 2025
Quick facts
| Lead sponsor | Hospital Universitario Doctor Peset |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 May 2019 |
| Primary completion | 1 August 2025 |
| Estimated completion | 1 October 2025 |
| Sites | 3 locations across Spain |
Drugs / interventions tested
- modified TPF — full drug profile →
- Quality of life assessment (QoL)
Conditions studied
- Locally Advanced Head and Neck Squamous Cell Carcinoma — all drugs for Locally Advanced Head and Neck Squamous Cell Carcinoma →
Sponsor
Hospital Universitario Doctor Peset
Who can join
18 and older, any sex, with Locally Advanced Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
objective response rate (ORR)
Time frame: 12 weeks after radiotherapy termination
percentage of partial and complete response rates (RR)
Sponsor's own description
The purpose of the study is to evaluate the efficacy and safety of induction mTPF chemotherapy followed by concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck cancer
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Zheng S, Feng Y, Li C, Zhang J, et al · · 2023 · cited 5× · PMID 36943658 · DOI 10.1007/s40487-023-00226-7
Verify or expand the search:
- PubMed search for NCT05527782
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Locally Advanced Head and Neck Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT07524452 — Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, · Phase 3 · recruiting
- NCT07369882 — Comparison of Efficacy Between De-escalated Surgery and Standard Surgery After Neoadjuvant Immunotherapy in Locally Adva · NA · recruiting
- NCT07371234 — Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck · Phase 2 · recruiting
- NCT06470217 — Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma · Phase 2 · recruiting
- NCT06240689 — A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy f · Phase 2 · recruiting
Other Hospital Universitario Doctor Peset trials
Trials by the same sponsor.
- NCT06309381 — Influence of Sensory Block Duration on Rebound Pain After Outpatient Foot Surgery Under Popliteal Sciatic Nerve Block. · completed
- NCT05356299 — Analysis of the Magnetic Tape Bandage on Respiratory Functional Effects. · NA · unknown
- NCT03079466 — Effect of CPAP Treatment on the Elderly With Mild to Moderate Sleep Apnea · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05527782 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitario Doctor Peset
- Last refreshed: 22 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05527782.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing